· Published by Health Canada · Official notice
This is duplicated text of a letter from Abbott Laboratories, Limited.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
May 14, 2007
Subject: Urgent Product Recall Voluntary Type I Recall of Depakene® (valproic acid) 500-mg Enteric-Coated Capsules in Canada
Dear Patient:
Abbott Laboratories, Limited (Abbott) and Health Canada are advising the public of a voluntary recall of Depakene® (valproic acid) 500-mg enteric-coated capsules. Depakene® (valproic acid) is a prescription medication used to treat epilepsy. Routine product testing indicated that the product's shelf-life is not as long as marked on the packaging. As a result, a lesser amount of active ingredient may be released. This may result in inadequate seizure control, potentially putting patients at risk for a greater number of seizures.
In addition, due to changes in manufacturing availability, Depakene® (valproic acid) 500-mg enteric-coated capsules is permanently discontinued as of May 11, 2007 and will no longer be available in Canada.
No other Depakene® formulation or Abbott product is affected by this action.
Patients must return Depakene® (valproic acid) 500-mg enteric-coated capsules to their pharmacists.
As with any drug product, in order to avoid contaminating ground or municipal water systems, the product should not be flushed down the toilet or sink.
Abbott has sent a letter to Canadian health care professionals notifying them of this important voluntary recall. You may view this letter on the Abbott website at http://www.abbott.ca. The Public Communication will be also posted on Health Canada website.
Abbott reiterates its commitment to the health and safety of patients and the delivery of quality products.
Should you have any questions or require additional information regarding the recall of Depakene® (valproic acid) 500-mg enteric-coated capsules, please contact your health care provider.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse reactions in patients receiving Depakene® (valproic acid) 500-mg enteric-coated capsules should be reported to Abbott or Health Canada at the following addresses:
Abbott Laboratories, Limited
Medical Information Department
8401 Trans-Canada Highway
Saint-Laurent, Quebec H4S 1Z1
Tel : 1-800-567-2226
Fax : 514-832-7824
Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
Health Canada
Address Locator: 0701C
Ottawa, Ontario, K1A 0K9
Tel: 613-957-0337 or Fax: 613-957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866-234-2345
Fax: 866-678-6789
cadrmp@hc-sc.gc.ca
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
For other inquiries related to this communication, please contact Health Canada at:
Health Products and Food Branch Inspectorate - Drug Compliance Verification & Investigation Unit (DCVIU)
E-mail: DCVIU_UVCEM@hc-sc.gc.ca
Telephone: 613-941-3967
Fax: 613-952-9805